Free Trial
NASDAQ:NMRA

Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Neumora Therapeutics logo
$0.73 -0.02 (-3.12%)
As of 06/30/2025 04:00 PM Eastern

About Neumora Therapeutics Stock (NASDAQ:NMRA)

Key Stats

Today's Range
$0.72
$0.78
50-Day Range
$0.62
$1.09
52-Week Range
$0.61
$17.19
Volume
1.01 million shs
Average Volume
1.52 million shs
Market Capitalization
$118.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.29
Consensus Rating
Hold

Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

NMRA MarketRank™: 

Neumora Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 617th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neumora Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Neumora Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Neumora Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neumora Therapeutics are expected to grow in the coming year, from ($1.61) to ($1.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neumora Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neumora Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neumora Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Neumora Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    22.30% of the float of Neumora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neumora Therapeutics has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neumora Therapeutics has recently decreased by 3.20%, indicating that investor sentiment is improving.
  • Dividend Yield

    Neumora Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Neumora Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.30% of the float of Neumora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neumora Therapeutics has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neumora Therapeutics has recently decreased by 3.20%, indicating that investor sentiment is improving.
  • News Sentiment

    Neumora Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Neumora Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    5 people have searched for NMRA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neumora Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.80% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neumora Therapeutics' insider trading history.
Receive NMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NMRA Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
See More Headlines

NMRA Stock Analysis - Frequently Asked Questions

Neumora Therapeutics' stock was trading at $10.60 at the start of the year. Since then, NMRA stock has decreased by 93.1% and is now trading at $0.7333.
View the best growth stocks for 2025 here
.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its earnings results on Monday, May, 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02.
Read the conference call transcript
.

Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.

Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP).

Company Calendar

Last Earnings
5/12/2025
Today
7/01/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NMRA
Fax
N/A
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.29
High Stock Price Target
$20.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+1,166.3%
Consensus Rating
Hold
Rating Score (0-4)
2.22
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$243.79 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.78 per share
Price / Book
0.41

Miscellaneous

Free Float
118,400,000
Market Cap
$118.61 million
Optionable
Optionable
Beta
2.74
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:NMRA) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners